MBRXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Moleculin Biotech, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$0.27−0.02 (-5.49%)
Close on Oct 19, 2026
- Market cap
- $1.51M
- P/E (TTM)
- –
- Dividend yield
- –
Margins need revenue and profit figures
This company does not report the lines needed to calculate margins.
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2016 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | -55.2% | -104.1% | -256.0% | |
| Return on assets | -47.8% | -64.0% | -171.9% | |
| Current ratio | 3.88 | 5.89 | 1.41 | |
| Diluted shares | 0M | 0M | 1M |
Where the cash went
Fiscal 2021 to 2025, five years combined
Moleculin Biotech generated $116.78M from operations and spent $223.00K on capital expenditure, dividends and share buybacks. 100% of that went back into the business.
Generated
$116.78M
Used
$223.00K
Capital expenditure$223.00K100%Dividends$00%Share buybacks$00%
DuPont needs revenue, assets and equity
This company does not report all three for consecutive years.
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
2of 7 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero-$33.56M
- Cash generatingOperating cash flow above zero-$22.74M
- Return on assets improvedROA up on the prior year-68.2% → -198.3%
- Earnings backed by cashOperating cash flow above net income-$22.74M vs -$33.56M
- Less leverageLong-term debt to assets fell– → –
- Better liquidityCurrent ratio rose0.97 → 1.41
- No dilutionShare count did not rise0M → 1M
- Gross margin improvedGross margin up on the prior year– → –
- More efficientAsset turnover rose0.00 → 0.00